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Abstract
Yersinia pestis dissemination in a host is usually studied by enumerating bacteria in the tissues of animals sacrificed at
different times. This laborious methodology gives only snapshots of the infection, as the infectious process is not
synchronized. In this work we used in vivo bioluminescence imaging (BLI) to follow Y. pestis dissemination during bubonic
plague. We first demonstrated that Y. pestis CO92 transformed with pGEN-luxCDABE stably emitted bioluminescence in vitro
and in vivo, while retaining full virulence. The light produced from live animals allowed to delineate the infected organs and
correlated with bacterial loads, thus validating the BLI tool. We then showed that the first step of the infectious process is a
bacterial multiplication at the injection site (linea alba), followed by a colonization of the draining inguinal lymph node(s),
and subsequently of the ipsilateral axillary lymph node through a direct connection between the two nodes. A mild
bacteremia and an effective filtering of the blood stream by the liver and spleen probably accounted for the early bacterial
blood clearance and the simultaneous development of bacterial foci within these organs. The saturation of the filtering
capacity of the spleen and liver subsequently led to terminal septicemia. Our results also indicate that secondary lymphoid
tissues are the main targets of Y. pestis multiplication and that colonization of other organs occurs essentially at the terminal
phase of the disease. Finally, our analysis reveals that the high variability in the kinetics of infection is attributable to the
time the bacteria remain confined at the injection site. However, once Y. pestis has reached the draining lymph nodes, the
disease progresses extremely rapidly, leading to the invasion of the entire body within two days and to death of the
animals. This highlights the extraordinary capacity of Y. pestis to annihilate the host innate immune response.
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Introduction
Plague is an infectious disease caused by the Gram-negative
bacillus Yersinia pestis [1]. The incidence of the disease has
gradually decreased during the course of the third pandemic that
started from Hong Kong in 1894. However, since the 1990’s,
human plague reappeared in countries where no cases had been
reported for decades, and thus the plague is now categorized as a
re-emerging disease [2]. Rodents are the main plague reservoir
and the disease is transmitted from rodent to rodent via the bite of
infected fleas [3]. Humans, which are incidental hosts of Y. pestis,
are most commonly infected after the inoculation of the bacillus
into the dermis during a fleabite. This mode of Y. pestis penetration
generally gives rise to the development of the most common form
of infection, bubonic plague, which is characterized by the
appearance of a painful and inflammatory lymph node, the
pathognomonic bubo. The infection then spreads to various
organs, leading to a terminal and fatal septicemia. In the absence
of treatment, bubonic plague lethality varies from 50 to 70% [4].
Various animal models are utilized to study plague pathogenesis
(mice, monkeys, rats, etc.) [5–9], the most widely used being the
mouse experimental model. This model is appropriate and reliable
to study a natural Y. pestis infection, as rodents are the normal hosts
for Y. pestis. To follow disease progression, the conventional
method is to experimentally infect mice with Y. pestis, sacrifice
groups of animals at various time intervals, and determine
bacterial counts in their tissues. This methodology has brought
valuable information about the mode of Y. pestis spread during the
infectious process, but it is laborious and time consuming, as it
requires to collect various organs at various times post-infection, to
crush them, to prepare serial dilutions of the tissue suspensions, to
streak them on agar plates, and to count the bacterial colonies.
Moreover, with this method, bacterial dissemination can be
followed only in the tissues that have been collected. Most
importantly, this approach suffers from a serious drawback
attributable to intrinsic variations of biological systems. Indeed,
the kinetics of bacterial spread and the fatal outcome greatly vary
from one animal to another, even when inbred mouse strains are
used. It is thus not possible to accurately follow disease progression
as, at a given time of sacrifice, the animals are at different phases of
the pathological process. One way to partly circumvent this
biological variability is to use large cohorts of animals in order to
obtain statistically significant data. This approach may bring
reliable results, but is labor-intensive, expensive, and goes against
the Animal Care standards and the current trend to reduce as
much as possible the number of animals used for experimental
studies. Other ways to limit biological variability include the
injection of bacteria at very high doses or through artificial routes
(intravenously or intraperitoneally), thus allowing a more rapid
bacterial spread and therefore a narrower window of variation.
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generate pathological processes that do not accurately reflect the
normal course of the bubonic infection [10].
The recent advent of in vivo bioluminescence imaging (BLI), that
allows tracking the spread of inert particles or microorganisms in
live animals, has been a step forward in the study of physiological
and pathological processes. This technology has been successfully
applied to the analysis of various viral, bacterial and fungal
infections [11–14], including diseases caused by category A
biowarfare bacterial agents such as Bacillus anthracis [15] and
Francisella tularensis [16]. This technique relies on the introduction
into a bacterium of genes encoding an enzyme that, in the
presence of its substrate, catalyzes a reaction generating biolumi-
nescence. The light emitted by the recombinant microorganism is
measured using an in vivo BLI system. The bioluminescence tool
has recently been applied to members of the genus Yersinia. For
instance, the impact of a partial deletion of the pYV-encoded
YopE protein on the course of a Yersinia pseudotuberculosis infection
in BALB/c mice was followed using recombinant bacteria
carrying on the pYV plasmid, the luxCDABE locus that encodes
the luciferase and its substrate [17]. More recently, monitoring of
gene expression during a Y. pseudotuberculosis infection was made
possible after inserting various gene promoters upstream of the
luxCDABE operon [18]. In Yersinia enterocolitica, a strain in which the
luxCDABE operon has been inserted into the chromosome allowed
tracking of the bacteria in living animals and comparison of the
fate of the wild type strain to that of an inv mutant derivative [19].
In this study we first determined whether a bioluminescent Y.
pestis could be a reliable tool to perform in vivo imaging, and we
subsequently used this recombinant strain to study bubonic plague
progression in a mouse model of experimental infection.
Results
Construction of a bioluminescent Y. pestis strain
A bioluminescent clone of Y. pestis was obtained by introduction
of plasmid pGEN-luxCDABE, which harbors the luxCDABE operon
from Photorhabdus luminescens under the control of the Pem7
promoter [12] into the virulent Y. pestis strain CO92, yielding
CO92(pLux). Bioluminescence emission by the recombinant strain
grown on LBH-Carb agar plates was checked with the IVIS 100
device. A luminescence signal was emitted by all CO92(pLux)
colonies on the plate, while no signal was detected in the CO92
wild-type strain (Figure 1). Similarly, CO92(pLux) but not CO92
grown in broth emitted a bioluminescence signal detected with a
Xenius plate reader (data not shown). The luxCDABE operon is
thus functional in Y. pestis.
Evaluation of the bioluminescence tool under in vitro
conditions
Since exogenous plasmids may impair Y. pestis multiplication, the
growth kinetics in LB broth of CO92 and CO92(pLux) were
followed over a two-day period. Both strains exhibited similar
growth kinetics (Figure S1). A slight delay in bacterial multiplication
was observed between 24 h and 28 h of growth. However, this
growth delay disappeared after 30 h (P$0.2 for the median cfu of
CO92 and CO92(pLux) according to the Mann Whitney test).
The linear relation between light intensity and cfu counts was
calculated using a large range of bacterial concentrations. For this
purpose, CO92(pLux) was grown on LBH-Carb agar plates at
28uC, suspended in LB broth, and serially diluted from 7.5610
1 to
7.5610
8 cfu/ml. Each dilution was used to quantify the intensity
of bioluminescence produced. As shown on Figure S2.A, a linear
relationship between cfu and light emission was obtained for
bacterial concentrations $7.5610
4 cfu/ml. After logarithmic
transformation of light intensity and cfu counts $7.5610
4 cfu/
ml, the Pearson two-tailed test indicated a highly significant
correlation (P,0.0001). Light signals generated by bacterial
concentrations below 7.5610
4 cfu/ml represented the background
level, which was around 175 photons/s.ml. The correlation
between cfu and light emission was further analyzed in actively
multiplying bacteria. Aliquots of CO92(pLux) growing in LB-Carb
broth were taken at various time points to both quantify
bioluminescence emission and determine cfu counts. A robust
correlation (P,0.0001) between the two sets of data was again
observed (Figure S2.B). The intensity of the bioluminescent signal
could thus provide an accurate estimate of the number of cells for
bacterial concentrations $7.5610
4 cfu/ml.
The luxCDABE operon is under the control of the Pem7
promoter, which is constitutive in E. coli [12]. Since Y. pestis has to
adapt to different environments and temperatures during its life
stage in the flea (21–30uC) and in a mammalian host (37uC), we
considered whether expression of luxCDABE would be constitutive
in this species, or whether it would be temperature-dependent. As
shown on Figure S3, the amount of light per cfu was significantly
higher when bacteria were grown at 37uC than at 28uC, both on
agar plates and in broth. These results suggest that the
temperature of the mammalian host might be favorable for an
efficient production of luciferase activity.
The stability of pGEN-luxCDABE and of the bioluminescence
signal over time and bacterial division was determined by
performing 13 subcultures of CO92(pLux) in LB broth without
carbenicillin over 19 days. At different time points (day 0, 3, 5, 7,
10, 12, 14, 17 and 19), bacterial aliquots were streaked on LBH
plates and individual colonies were checked for their capacity to
grow in the presence of Carb (maintenance of the pGEN-
luxCDABE plasmid), and to emit luminescence (maintenance of the
luciferase activity). The proportion of pGEN-luxCDABE-harboring
Figure 1. Bioluminescence imaging of Y. pestis. Y. pestis CO92 or
CO92(pLux) were grown for 48 h at 28uC on LB-Carb plates. The plates
were placed in an IVIS 100 device dark chamber, photographed under
normal light and then bioluminescence emission was detected using a
7 s exposure time and a picture binning of 4. Both pictures were
superimposed by the Living image software. Colored dots represent
bioluminescence emitting bacteria. The color bar on the right shows
the intensity of bioluminescence light coded in the picture from indigo
(4.1610
7 photon/s.cm
2.steradian) to red (6.9610
8 photon/s.cm
2.ster-
adian).
doi:10.1371/journal.pone.0034714.g001
In Vivo Tracking of Y. pestis
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all emitted light (data not shown), indicating a high stability of
bioluminescence emission in CO92(pLux) under in vitro conditions.
Evaluation of the bioluminescence tool under in vivo
conditions
The potential impact of the presence of pGEN-luxCDABE on Y.
pestisvirulencewas evaluatedinthe mousemodelofbubonicplague.
The presence in the recombinant CO92(pLux) strain of the major
virulence factors that are easily lost in Y. pestis (pPla, pYV and the
HPI) was confirmed by PCR prior to infections. The LD50 by the
subcutaneous (sc) route of CO92(pLux) was similar to that of the
wild-typeCO92(,10 cfuforbothstrains).Thesurvivalcurveswere
also similar (Figure S4), with no statistical difference (Mantel-Cox
test) in animals infected with 10 cfu (P=0.63) or 100 cfu (P=0.19)
of eitherstrain, indicating that thepresence ofpGEN-luxCDABEdid
not affect the virulence of Y. pestis upon sc infection.
The maintenance of the plasmid and of the capacity of
CO92(pLux) to emit light upon in vivo multiplication was verified
by analyzing bacteria recovered from the spleen and liver of two
moribundmiceonday5.All300coloniestested(200recoveredfrom
the spleen and 100 from the liver) grew on LBH-Carb plates and
emitted light (data not shown), indicating that the plasmid and the
luminescence activity were retained during in vivo growth of Y. pestis.
To determine whether the bioluminescence signal emitted by Y.
pestis was sufficient to be detected during the infectious process,
mice were infected sc with 100 cfu of strain CO92(pLux). The
animals were anesthetized and monitored daily for biolumines-
cence emission with the IVIS 100 device. A signal was visible at
the injection site from the first observation (24 h post-infection)
and appeared in other locations in the following days (Figure 2A),
indicating that the bioluminescent signal emitted by CO92(pLux)
could be used to track Y. pestis dissemination in vivo.
To link the signal sources to the colonization of specific organs,
infected mice were bioluminescence-monitored at different times
post-infection (pi). They were subsequently sacrificed, dissected to
expose the organs, and monitored again. The luminescent signals
observed in live animals in a dorsal position matched those of the
anatomical sites (injection site, liver, axillary and inguinal lymph
nodes) from which the signal was predicted to be emitted (Fig. 2B).
Bacterial colonization of the spleen was best visualized when the
animals were placed in ventral position.
Next we wanted to determine whether the amount of
bioluminescence emitted from the inguinal lymph nodes, spleen
and liver of live animals correlate with bacterial loads. For this
purpose 14 mice were infected sc with 100 cfu of CO92(pLux),
they were bioluminescence-monitored at different time points, and
the radiance from the region of interest (ROI) defining each organ
was measured. The animals were immediately sacrificed after-
wards and their organs were removed and crushed to determine
cfu counts. Light emission increased with bacterial burden in the
three organs (Figure 3), and according to the Pearson test, the
number of bacteria significantly correlated with the intensity of
light emission in these tissues (inguinal lymph nodes: P=0.0392,
spleen: P,0.0001, liver: P=0.0017). The higher P value observed
for the inguinal lymph nodes might be at least partly attributable
to several nodes that emitted light while no cfu were obtained
(triangles below the detection limit on Figure 3A). This could be
due to a technical problem linked to the difficulty to differentiate
the inguinal lymph nodes from the surrounding fat tissue in some
mice. A removal of these probably falsely cfu-negative nodes
would have further improved the correlation between bacterial
loads and light emission. Nevertheless, our results indicate that
bioluminescence quantification can provide reliable non-invasive
measures of Y. pestis burden in the organs of infected live animals.
To obtain data that could be used to compare disease
progression between mice, as well as at different times pi in the
same mouse, a predefined standard setting ranging from 7610
5 to
5610
8 p/sec/cm
2/sr was selected and used for all in vivo
measurements of bioluminescent signals in live animals. This
range of radiance was chosen to avoid most of background light
(lower setting high enough), while reflecting a wide dynamic scale
(the highest upper setting that still permitted contrast). Using this
predefined setting, the minimal amounts of bacteria that allowed a
signal detection were 8.3610
5 cfu for the spleen, 1.3610
5 cfu for
the liver, and 1.5610
4 cfu for the inguinal lymph nodes.
Figure 2. Linking a bioluminescence signal to the colonization of a specific organ. (A) Example of the light emitted by a live animal. (B)
Light emitted by the organs of the same animal. Arrows point at: (1) axillary lymph nodes, (2) liver (one lobe still in place and the remaining of the
organ removed from its anatomical site), (3) injection site (split in two parts during dissection), (4) inguinal lymph nodes, and (5) spleen (removed
from its anatomical site and visualized in live animals mostly in ventral position). On the dissection picture, the gut has been removed and placed
next to the right hind leg, while the peritoneum including a portion of the infection site is located next to the left hind leg. Color bars on the right of
each picture show the intensity of bioluminescence light coded in the picture from indigo to red.
doi:10.1371/journal.pone.0034714.g002
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Once the characteristics of the bioluminescent tool were defined
and its suitability to track Y. pestis in live animals confirmed, we
used this tool to follow the course of bubonic plague in individual
animals. BALB/cByJ female mice were infected sc in the linea alba
with 100 cfu of CO92(pLux) on day 0 (D0), and the animals were
anesthetized and monitored daily for bioluminescence emission
from D1 until their death, using our defined IVIS settings. To limit
the effect of individual variations inherent to live biological
systems, a large group of mice (46 animals) was used in six
independent experiments, and the data were pooled and analyzed.
The bioluminescent signal followed the same route of spread in
most animals (74%), allowing to delineate successive steps and to
draw a general scheme of dissemination. An example of each of
these steps is shown on Figure 4. A signal, already visible in all
animals on the first day of observation (D1), was initially limited to
the site of injection (Figure 4A). The second site to emit light was
the inguinal lymph node either on one side or on both sides of the
animal (Figure 4B). The following luminescent organs were the
ipsilateral axillary lymph nodes (Fig. 4C). A light-emitting line
running between the inguinal and axillary lymph nodes was
sometimes visible both on live and necropsied animals (Figure 5A),
suggesting a direct connection between the two lymph nodes via
the lymphatic vessels. To visualize this route of lymphatic
drainage, 100 ml of a 5% Evans Blue solution were injected sc in
the linea alba of four mice. The animals were sacrificed 1, 10, 20 or
30 min after the injection to follow the fate of the dye. The two
lymph nodes were stained in blue and a thin, pale vessel also
colored in blue and connecting the two lymph nodes was visible
adjacent to the blood vessels (Fig. 5B). These results are consistent
with a route of bacterial dissemination starting from the injection
site and using the lymphatic stream to reach first the inguinal
lymph node and then the axillary lymph node. Next, the
bioluminescence extended to the sub diaphragmatic zone
identified as the liver region, and a spot corresponding to the
spleen was also visible on the back of the animals (Figure 4D,
dorsal and ventral position). A bioluminescence of the entire
animal, including peripheral sites such as the tail or the ears
(Figure 4E), highly evocative of a septicemic stage was then
observed. This terminal septicemia, which was confirmed by the
recovery of circulating Y. pestis from the blood, was systematically
followed by the death of the animals.
Exceptions to this general scheme were a limitation of the signal
to the injection site until the animal death (11% of the mice) or a
direct colonization of the inner organs without visualizing the
lymph node steps in 15% of the animals, both suggestive of a direct
passage of the bacteria in the blood.
Of note, no signal at anatomical sites corresponding to the
intestine, the lungs or the kidneys were detected on living animal
before the final septicemic phase. This was in accordance with the
absence of bioluminescence detected in these organs when animals
were autopsied (Figure 2B).
Kinetics of bacterial progression during bubonic plague
To determine the kinetics of bacterial spread in our mouse
model of bubonic plague, the average time at which the
anatomical sites started to emit light was calculated for 24
individual mice for which all data were available from D1 until
their death. The injection site was always bioluminescent from the
first day of observation (D1) in all animals. On average, the signal
appeared on D3 in the inguinal lymph node (D3.360.4) and soon
after in the axillary lymph node (D3.660.4) (Figure 6). The next
affected organs were the spleen and liver, which both started to
emit light around D4 (4.160.3 and 3.960.3, respectively). Their
colonization was followed on D5 (560.6) by a bioluminescence of
the entire body, characteristic of a septicemic phase. Because of
the very short period of time elapsed between invasion of the
whole body and death, the septicemic phase could not always be
observed with our daily monitoring window. The death of the
animals occurred on average around D6 (5.860.4).
This chronology of bacterial dissemination allowed estimating
of the average time at which the colonization of each organ
occurred in a group of animals. However, our observations also
evidenced important differences from one animal to another. The
constant feature was that all mice emitted light at the site of
injection on D1, and that the signal was restricted to this site in all
except one animal at this early time point (Figure 6). After D1,
large variations in the times at which the various colonization steps
occurred were observed. For instance, the time of the first light
emission in the inguinal lymph node varied from D1 to D7 in
different animals. Similarly, a variation of 6 days was observed for
the appearance of bioluminescence in the axillary lymph node, of
4 days in the spleen and liver, of 3 days for the whole body and of
6 days for the fatal outcome. These results reflect a high variability
in the rapidity of dissemination of the bacteria in each animal.
Despite this variability, the analysis of the time interval elapsed
between the appearance of a signal at two consecutive steps during
disease progression for each individual mouse revealed a
Figure 3. Correlation between bioluminescence emission by specific organs in live animals and cfu counts. Live animals were
monitored for bioluminescence emission and subsequently sacrificed at various times pi. Their inguinal lymph nodes, spleen and liver were taken to
determine the bacterial load in each organ. Each point accounts for one organ taken from an infected animal. The continuous line represents the
least square fit linear regression, and the related goodness of fit coefficient (R
2) is indicated on each graph. The horizontal dotted line indicates the
detection limit of the bacterial load (10 cfu).
doi:10.1371/journal.pone.0034714.g003
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inguinal lymph nodes could take up to 7 days, once this site started
to emit light, the kinetics of dissemination to other organs was
remarkably constant in all animals. Indeed, from the lymph nodes,
the signal reached the liver and spleen within one day (160.2), the
entire body (septicemic phase) in two days (260.5), and the animal
died soon after (D2.260.3). All animals seen at the septicemic
phase were systematically found dead on the next day. In a few
cases, the disease progressed even faster and the window frame of
one day did not allow to visualize the intermediate steps between
lymph node colonization and the terminal phase of the infection.
Therefore, our results revealed two important phenomena: (i) the
variations in the kinetics of bacterial spread were essentially
attributable to the length of time the signal remained limited to the
injection site, and (ii) as soon as the signal reached the lymph
nodes, the disease progressed very rapidly, leading to the animal
death within two days.
Discussion
Past studies performed at the post-mortem stage on autopsied
human plague victims have been invaluable for understanding
pathological processes that took place during bubonic plague.
However, they were performed after the terminal phase of the
disease, when the entire body was colonized, and therefore the
mode of Y. pestis dissemination could not be clearly established.
Figure 4. Different steps of bacterial spread during bubonic plague. The bioluminescent signal was visible first at the injection site (A). It
then reached the inguinal lymph node (B), the axillary lymph node (C), the liver (D, dorsal position) and the spleen (D, ventral position), and finally the
entire body (E). Each picture is an example of an animal displaying a signal characteristic of each step. The color scale on the right represents the
settings used to monitor light emission in all mice throughout the observation period.
doi:10.1371/journal.pone.0034714.g004
Figure 5. Lymphatic connection between the inguinal and axillary lymph nodes. (A) Observation of a bioluminescent signal connecting
the two lymph nodes on a live and on a necropsied mouse. (B) Staining of the lymphatic system after injection in the linea alba of the Evans blue dye.
The axillary and inguinal lymph nodes are stained in blue and the lymphatic vessel draining the two nodes is seen as a thin pale blue line adjacent to
the blood vessels.
doi:10.1371/journal.pone.0034714.g005
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information. However, they only give snapshots of the infection, as
the infectious process is not synchronized in all animals. Indeed,
follow up of bacterial infection progression is most often hampered
by the biological variability inherent to animal models. This
phenomenon is exemplified by the fact that the LD50, commonly
used as a means for quantifying bacterial virulence, relies on the
fact that a similar bacterial inoculum will be lethal for only half of
the animals, even if they have an identical genetic background
(syngenic mice) and are kept under similar conditions. In addition,
when physiological doses and routes of inoculation are utilized,
variations in time to death are commonly observed. This lack of
synchronization makes the analysis of bacterial spread, tissue
lesions or innate immune response difficult, as the animals are not
at the same phase of the infectious process at the time of sacrifice.
Tracing bacterial spread through the monitoring of a biolumines-
cent signal can bring a technical answer to this issue. The use of in
vivo imaging has been applied to the study of various bacterial
infections and has revealed some pathophysiological processes that
had not been previously seen using conventional methods [12,15].
This technique is much simpler and less time consuming than
methods relying on bacterial isolation and enumeration from
different organs. It has also the advantage over conventional
methods based on the sacrifice of groups of animals at given time
points to make possible both reduction and refining of animal use,
two of the ‘3R principles’ of Russell and Burch [20].
The aim of this work was to use the in vivo BLI technology to
gain a deeper knowledge of the mode of Y. pestis dissemination
during bubonic plague. Since bioluminescence has never been
used to track Y. pestis during the infectious process, the first step of
this study was to determine its applicability to the plague bacillus.
The capacity of Y. pestis to emit bioluminescence in vitro was
previously shown after insertion of the luxAB genes downstream of
the ymt or caf promoters in strain EV76 [21]. Similarly, we
observed here that a Y. pestis CO92 carrying pGEN-luxCDABE,a
low-copy number plasmid that encodes the luciferase enzyme and
its substrate [12], gained the capacity to emit light during growth
in broth or on agar plates.
However, this technology would only be applicable if the
plasmid carrying the lux operon is stable and if the bioluminescent
signal does not wane with bacterial division in vitro or in vivo.W e
found that the pGEN-luxCDABE plasmid was kept and the
luciferase activity was retained in 95% of the colonies despite
repeated Y. pestis subcultures in vitro, and in 100% of the colonies
upon multiplication in mouse organs. Introduction of exogenous
plasmids into Y. pestis may impair its virulence [22]. Moreover, the
product of luxD has been found to be toxic in mycobacteria, most
likely because, in conjunction with the products of luxC and luxE,i t
forms part of an enzyme complex which alters the cell wall
structure of these bacteria [23]. We found that neither the
presence of the pGEN-luxCDABE plasmid, nor the luciferase
activity had an impact on the kinetics of bacterial growth in vitro
and on the virulence of Y. pestis in the mouse experimental model
of bubonic plague.
The luciferase activity produced by Y. pestis CO92(pLux) during
the infectious process was high enough to generate a light signal
that was detectable by the IVIS. Moreover, the assignment of a
specific organ to each light spot based on its anatomical location in
live mice was confirmed after animal dissection and organ
exposure, thus indicating that the bioluminescent signal could be
used to track Y. pestis progression in the mouse experimental model
of bubonic plague. In other infection models, the intensity of light
emission did not systematically give an accurate estimate of
bacterial loads in various organs. While a good correlation
between these two parameters was observed during inhalational
and intestinal anthrax [15], or in the neutropenic mouse thigh
model of Escherichia coli infection [24], this was not the case in the
Streptococcus pneumoniae lung infection model for instance [25]. We
found here that Y. pestis cfu counts and light intensity emitted by
infected organs (lymph nodes, spleen and liver) in live mice were
significantly correlated, thus providing a reliable picture of the
route of bacterial dissemination.
To study the kinetics of bacterial spread in the same animal and
to compare disease progression in different animals and at
different time points, we decided to use a predefined standard
light setting that was not too sensitive to minimize background
luminescence while providing a good contrast between light
emitting spots. Using this setting, the detection limit ranged from
<10
4 to 8610
5 cfu depending on the organ. Hence, an absence of
light emission in an organ means that the bacterial load is below
this threshold, and not necessarily that there is a complete absence
of bacteria in this organ. Similar thresholds have been reported in
the rat endocarditis model of Staphylococcus aureus infection [26].
Having demonstrated that a bioluminescent Y. pestis strain could
be used for in vivo BLI, we applied this technology to the analysis of
bubonic plague development in live mice. The use of a large set of
animals allowed us to confidently draw a general scheme of Y. pestis
dissemination. Our results indicate that the first step of the
infectious process is a bacterial multiplication at the site of
injection in the linea alba. This step is followed by a colonization of
the draining inguinal lymph node, in accordance with the clinical
descriptions of bubonic plague in humans, characterized by a
bubo draining the site of the flea bite [4]. Since we performed the
sc injection approximately in a median line on the abdomen,
either a unilateral or a bilateral infection of the inguinal lymph
nodes was observed. The next site colonized is the ipsilateral
axillary lymph node. This route of dissemination from the initial
draining lymph node (designated primary bubo of first order) to
the next one located on the same side (primary bubo of second
order) was suggested by pathological examinations of patients who
died of bubonic plague [4,27]. Since these analyses were done at a
post-mortem stage characterized by an invasion of the whole body,
the direct migration from the initial bubo to the contiguous lymph
node could not be fully established. The fact that we observed a
bioluminescent line connecting the two lymph nodes at an early
stage of the infection demonstrates that this route of spread is
Figure 6. Time of appearance of a bioluminescent signal in the
various organs of infected mice. Each circle corresponds to an
individual animal. Horizontal bars represent the mean and vertical bars
the standard error of the mean of the data collected from 24 mice. LN:
lymph node.
doi:10.1371/journal.pone.0034714.g006
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the two nodes [28], and our visualization of lymph vessels linking
them, strongly suggest that the bacteria use the lymphatic stream
to migrate from one lymph node to the next one. This route is also
supported by the observation that in a rat model of bubonic
plague, the bacteria penetrate into the primary bubo of second
order (corresponding to the ipsilateral axillary lymph node),
through the marginal sinus, which is drained by the afferent lymph
channels [9].
Next the infection progresses to the liver and spleen, which are
colonized almost simultaneously. This is consistent with previous
works reporting high bacterial loads in these organs in human
plague victims and animal models [4,9,27,29]. The colonization of
these lymphoid tissues requires a passage of the bacteria into the
blood circulation, either after a bacterial discharge into the
thoracic duct, or directly within the infected lymph nodes by in situ
disruption of the blood vessels. Arguing for the latter mode of
blood invasion is the observation of major hemorrhages with
disrupted blood vessels in the primary lymph nodes of infected
mice or rats [6,9]. This early bacteremia should be moderate and
transient, as no diffuse bioluminescent signal characteristic of a
heavy blood infection was observed prior to the infection of the
spleen and liver. An effective filtering of the blood stream by these
lymphoid organs may explain the early clearance of the bacteria
from the blood circulation and the ensuing development of
secondary bacterial foci within these organs. The saturation of the
filtering capacity of the spleen and liver coupled with massive in situ
bacterial multiplication subsequently leads to a terminal septice-
mia with an invasion of the entire body, as attested by a
luminescent signal emitted from the whole animal. This terminal
septicemic stage of bubonic plague has been largely documented,
both in human victims [4,27,30,31] and in non-human hosts
[5,8,9,29,32,33].
It is worth noting that anatomical sites other than secondary
lymphoid tissues did not emit light until the terminal septicemic
phase in live animals. Previous studies that quantified bacterial
loads in various tissues of experimentally infected animals showed
for instance that the lungs could be infected. When we performed
cfu counts from the lungs of necropsied animals, we could also
detect the presence of bacteria, but most of the time they were
present in low amounts (,10
4 cfu), and therefore below the
detection limit. Therefore, although this non-lymphoid organ
could be colonized, it does not seem to be a major site of Y. pestis
multiplication. It is possible that the bacteria recovered from the
lungs were from animals at the beginning of the systemic phase of
the infection. Altogether, in vivo BLI suggests that the main targets
of Y. pestis multiplication are the secondary lymphoid tissues
(lymph nodes, spleen and liver), and that colonization of other
organs is much less pronounced and may result from a secondary
septicemic spread, at the terminal stage of the infectious process.
The ability to follow the progression of the disease over time in
the same animal also allowed us to better define the kinetics of
infection. Our observations evidenced important animal-to-animal
variations in the rapidity of bacterial dissemination. Remarkably,
our analysis showed that the high individual variability in the
chronology of disease progression was directly linked to the time
the bacteria remained confined at the site of injection (1 to 6 days).
Impressively, once the bacteria had reached the lymph nodes, the
disease progressed extremely rapidly, leading to the invasion of the
entire body (septicemic phase) within two days and soon after to
the death of all animals. This highlights the extreme acuteness of
bubonic plague and the extraordinary capacity of Y. pestis to
disseminate through secondary lymphoid organs to cause an
extremely rapid and fatal septicemia.
In conclusion, the in vivo imaging, by tracking the spread of Y.
pestis in live animals, allowed us to draw a general scheme that
delineates the successive steps and kinetics of bacterial dissemina-
tion. This tool may have other promising applications, such as the
analysis of Y. pestis gene expression during disease progression, or
the study of the impact of gene mutations on the course of the
infectious process.
Materials and Methods
Bacterial strains and growth conditions
The fully virulent Y. pestis strain CO92 [34] and its derivatives
were grown in Luria Bertani (LB) broth for 24 h, or on LB agar
plates supplemented with 0.2% hemin (LBH) for 48 h at 28uC.
When necessary, carbenicillin (Carb; 100 mg/ml) was added to the
media. All in vitro experiments with Y. pestis were performed in a
Biosafety Level 3 laboratory. E. coli strain CFT073(pGEN-
luxCDABE) [12] was grown for 24 h at 37uC in LB-Carb broth.
Construction of a bioluminescent Y. pestis
Plasmid pGEN-luxCDABE [12], which carries the luxCDABE
operon and confers resistance to carbenicillin, was extracted from
strain CFT073(pGEN-luxCDABE) and introduced by electropora-
tion [35] into Y. pestis CO92, yielding CO92(pLux). Presence of
pGEN-luxCDABE in Carb
R colonies was checked by PCR with
primers 59-CCAGGTTGAAATCTTTCCCG-39 and 59-CTTT
TTGAACTAAAGAATAGGC-39, which amplify a portion of the
luxC gene. The maintenance of major and unstable virulence
factors was also checked by PCR with primers amplifying a
portion of Pla (59-ATCTTACTTTCCGTGAGAAG-39;5 9-
CTTGGATGTTGAGCTTCCTA-39), the pYV (59-ATAACT-
CATCGGGGGCAAAAT-39;5 9-GCGTTATTTATCCGAATT-
TAGC-39 that target yopM), or the High Pathogenicity Island
(HPI) (59-ATGCTGCATATCGCCTTTCGCCCCGAC-39;5 9-
GGACGTCGTGAATTTCGCAGGCGTTAGA-39 that amplify
irp2). Template DNA was obtained by suspending one bacterial
colony into 100 ml of 50 mM sodium hydroxide and 0.25%
sodium dodecyl sulfate, and heating at 95uC for 5 min. Each PCR
reaction was done in a volume of 50 ml containing 2 ml of template
DNA, 0.3 mM of each primer, 200 mM dNTP, 2 mM MgCl2,
1.25 U Taq Polymerase (Applied Biosystems) and 5 mlo f1 0 6
buffer. The PCR reactions comprised an initiation step of 5 min at
94uC; 35 cycles of 30 s at 94uC, 30 s at 55uC and 90 s at 72uC;
and a termination step of 10 min at 72uC. Bioluminescence
emission was detected and quantified with an In Vivo Imaging
System (IVIS 100, Caliper Life Sciences) and a Xenius plate
reader (SAFAS Monaco).
Mouse infections
Animals were housed at the Institut Pasteur animal facility,
which has been accredited by the French Ministry of Agriculture
to perform experiments on live mice (accreditation B 75 15-01,
May 22, 2008), in compliance with the French and European
regulations on care and protection of Laboratory Animals (EC
Directive 86/609, French Law 2001-486, June 6, 2001). The
protocol used in this study (#03.99, May 13, 2009) was approved
by the Hygiene & Security, and Veterinary Committees of the
Institut Pasteur, and was performed in compliance with the NIH
Animal Welfare Insurance (#A5476-01 issued on 02/07/2007).
Six- to eight-week-old BALB/cByJ mice (Charles River
Laboratories) were maintained under specific pathogen-free
conditions in a Biosafety Level 3 animal facility at the Institut
Pasteur, in compliance with the European animal welfare
regulations. Subcutaneous infections were performed by injecting
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alba. Bacterial counts were estimated by measuring the optical
density at 600 nm and confirmed by plating the suspensions on
LBH or LBH-Carb agar plates. The 50% lethal doses (LD50) were
determined using groups of five mice infected sc with 10-fold serial
dilutions of the bacterial suspensions. Animal deaths were followed
for three weeks and the LD50 was calculated according to the
method of Reed and Muench [36].
To quantify Y. pestis numbers in organs of infected animals or to
study pGEN-luxCDABE and bioluminescence maintenance after Y.
pestis multiplication in vivo, mice were infected sc with 100 cfu. At
various time points pi, the animals were sacrificed, their organs
were removed aseptically and crushed in a Mixer Mill MM 301
(Retsch). The suspensions were diluted in PBS and various
dilutions were streaked on LBH plates. Individual colonies were
streaked on LBH-Carb and light emission was determined with
the IVIS 100 device.
In vivo imaging
For in vivo tracking of Y. pestis, mice were infected sc with 100 cfu
of CO92(pLux). They were anesthetized every day by intraper-
itoneal injection of 200 ml of a solution containing 20 mlo f
ketamine (Imalgene 1000) and 10 ml of xylazine (Rompun 2%) in
saline. Mice were then set in a poly(methyl methacrylate)
confinement box (TEM SEGA) and introduced in an IVIS 100
system (Caliper Life Sciences). Image acquisition and analysis were
performed with the Living Image 3.2 software (Caliper Life
Sciences), using acquisition times of 1 s to 240 s to allow maximal
acquisition while avoiding signal saturation, and a binning set on
‘small’. To quantify the amount of light emitted by bioluminescent
bacteria in a specific organ, the region corresponding to this organ
(ROI or ‘‘region of interest’’) was defined in the software and the
average radiance of the defined region was calculated. To analyze
and compare the signals in a large number of animals, a
predefined setting ranging from 7610
5 p/sec/cm
2/sr to
5610
8 p/sec/cm
2/sr was used and applied to all measurements.
Visualization of lymphatic drainage
To visualize the lymph nodes and the draining lymphatic
vessels, a 5% (w/v) solution of Evans blue dye was injected into the
mouse linea alba. After 1 to 30 min, the mice were sacrificed and
the internal side of the skin extending from the lower to the upper
limbs was exposed to visualize the axillary and inguinal lymph
nodes.
Statistical analyses
Statistical analyses and the plotting of graphs were performed
using the software GraphPad Prism version 5.0d (San Diego,
USA). For correlations, data of cfu counts and light radiances were
processed as follows: after logarithmic transformation of both sets
of values, normality of the sampling was controlled by a d’Agostino
and Pearson omnibus normality test, and when the sample
distribution was normal, a Pearson two-tailed correlation test was
performed. When the correlation test was positive, a linear
regression was performed using the least square fit method.
Differences between bacterial concentrations or between ratios of
photons/cfu in in vitro conditions were analyzed with the Mann
Whitney test. Differences between survival curves were tested with
a log-rank (Mantel-Cox) test.
Supporting Information
Figure S1 Comparison of the growth kinetics of CO92
and CO92(pLux). CO92 (white circles) and CO92(pLux) (black
squares) were grown for 48 h at 28uC in LB broth and aliquots
were taken at various time points for bacterial counts. Shown are
mean values and standard error of the means (vertical bars) of
triplicate measures.
(PDF)
Figure S2 Correlation between bioluminescence emis-
sion and cfu counts. Bacteria were grown at 28uC on agar
plates (A) before being suspended in LB and serially diluted, or in
broth (B) and aliquots were taken at different time points to
determine bacterial counts and light emission. The line represents
the least square fit linear regression. The related goodness of fit
coefficient (R
2) is indicated on each graph.
(PDF)
Figure S3 Temperature-dependent expression of lux-
CDABE in Y. pestis. Bacteria were grown at 28uC (red circles)
or 37uC (blue triangles), in LB broth or on LBH agar plates. Each
spot represents the number of photons (count/s) emitted per cfu.
The horizontal bar represents the mean light emission per cfu and
the vertical bar the standard error. P values were determined with
the Mann Whitney test.
(PDF)
Figure S4 Survival curves of mice infected with Y. pestis
CO92 or CO92(pLux). Groups of five mice were infected
subcutaneously with approximately 10 cfu of Y. pestis CO92 (red
line) or bioluminescent Y. pestis CO92(pLux) (blue line) and their
mortality was followed daily.
(PDF)
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